• Tirzepatide, a medication developed by Eli Lilly, has shown successful results in a Phase 3 clinical study for the treatment of heart failure with preserved ejection fraction (HFpEF) in adults with obesity. The study found that tirzepatide significantly improved various measures of heart function and overall health outcomes in this patient population, providing a promising new treatment option for this challenging condition.

• The Phase 3 study enrolled 1,050 adults with HFpEF and a body mass index (BMI) of 30 kg/m2 or higher. Participants were randomized to receive either tirzepatide or a placebo, and the study's primary endpoint was the change in the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score, a measure of heart failure-related quality of life. The study results showed a statistically significant improvement in this primary endpoint for the tirzepatide group compared to the placebo group.

• In addition to the primary endpoint, the study also found that tirzepatide led to significant reductions in body weight, improvements in other measures of heart function, and a lower risk of cardiovascular-related hospitalizations. These findings suggest that tirzepatide may have the potential to address both the cardiovascular and metabolic aspects of HFpEF in adults with obesity, providing a comprehensive approach to managing this complex condition.